Journal of Clinical Oncology
Articles in this Issue
Overcoming HER2-directed antibody-drug conjugate resistance with disitamab vedotin in metastatic prostate cancer.
e17078 Background: Metastatic prostate cancer (PCa) is a highly aggressive disease with limited treatment options followin...
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
4614 Background: Enfortumab vedotin (EV) + pembrolizumab (pembro) is the established first-line standard of care for local...
Comparative analysis of large language models (LLMs) for pharmacogenomic (PGx)–guided prescribing in oncology.
e13665 Background: PGx is increasingly applied in oncology to personalize drug therapy, minimize toxicity, and improve eff...
Outcomes with adjuvant chemotherapy in patients with early-stage biliary tract cancers: An NCDB analysis.
e16302 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies, collectively associated with po...
Machine learning–based decision support for ICU admission in febrile oncology patients: Optimizing care delivery and resource allocation.
1598 Background: In febrile oncology patients, distinguishing self-limiting illness from life-threatening sepsis is a crit...
Center-level delivery patterns and capacity during rapid CAR-T expansion in the United States (2021-2023).
11089 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has rapidly expanded in the United States, accompanied...
Induction CAPOX as part of total neoadjuvant therapy for high-risk locally advanced rectal cancer: Long-term real-world outcomes from two centers.
e15650 Background: Recent randomised trials support total neoadjuvant therapy (TNT) for high-risk locally advanced rectal...
A phase I, open-label, dose-finding, safety, tolerability, and exploratory trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer.
TPS5635 Background: Ovarian cancers are immunologically cold at baseline and typically characterized by a rich stromal com...
RETRACTED: Neoadjuvant adebrelimab plus chemotherapy in untreated locally advanced head and neck squamous cell carcinoma: Efficacy and biomarker insights from a single-arm phase 2 trial.
6106 Background: Improving outcomes for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) requires novel s...
Role of routine prognostic blood tests in evaluating chances of safely prolonged survival across all ages.
e16348 Background: Prognostic blood tests (PBTs) are independent predictors of survival and often outperform traditional c...
Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
e21605 Background: As survival after cutaneous melanoma improves, subsequent primary malignancies (SPMs) and non-cancer co...
A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.
TPS2675 Background: Interleukin 2 (IL-2) is a cytokine involved in lymphocyte expansion and differentiation during the ant...
Real-world survival analysis of adolescent and young adult patients with hairy cell leukemia in the United States.
e19031 Background: Hairy cell leukemia (HCL) is a rare indolent B-cell malignancy with favorable outcomes. Adolescents and...
Impact of population-based testing for pathogenic variants in breast cancer genes on screening recommendations in the WISDOM study.
10512 Background: The relative contributions of pathogenic variants (PV) in breast cancer (BC) genes, polygenic risk score...
Patient demographics and germline mutation patterns across breast cancer molecular subtypes in a tertiary academic medical center: A retrospective study (October 2023–October 2025).
e13142 Background: Breast cancer is the most commonly diagnosed malignancy among women in the United States and continues...
Survival outcomes of patients with grade 4 IDH mutant astrocytomas: The UT MD Anderson experience.
e14092 Background: The WHO 2021 Classification of CNS Tumors distinguished IDH mutant (IDHmt) Grade 4 astrocytomas from ID...
Glucagon-like peptide-1 receptor agonist for primary prevention of hepatocellular carcinoma in high-risk patients: A real-world analysis across metabolic, viral, alcoholic, and hereditary liver disease.
10522 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality. While antiviral and metabolic the...
Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2− advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.
1075 Background: There is unmet need for therapies that improve clinical outcomes in patients (pts) with ER+/HER2− ABC and...
Phase 1 evaluation of the PRAME-targeted ImmTAC brenetafusp in advanced melanoma (Mel).
9527 Background: Brenetafusp (brene) is an ImmTAC bispecific (PRAME × CD3) therapy that promotes T cell recruitment into t...
Impact of neighborhood socioeconomic deprivation and diet quality on immune checkpoint blockade outcomes.
1545 Background: Immune checkpoint blockade (ICB) has significantly improved survival across multiple advanced malignancie...
Cancer patients’ knowledge and willingness for biospecimen donation at Prisma Health.
e22569 Background: Despite advances in precision medicine, cancer disparities persist among racial and ethnic minorities i...
Intracranial pharmacokinetics and resistance mechanisms of tucatinib in patients with HER2+/mutant solid tumors and brain metastasis: Results from the WinHER2 study (NCT05892068).
2031 Background: Tucatinib, a potent HER2-selective tyrosine kinase inhibitor approved for the treatment of HER2-positive...
Trends in income-related lung cancer disparities since the introduction of USPSTF screening guidelines.
8072 Background: In 2013, the USPSTF introduced guidelines for lung cancer screening to promote earlier detection. Prior s...
Imatinib-related toxicity profile in patients with gastrointestinal stromal tumors seen over a twenty-year period in Ile-Ife, Nigeria.
e23513 Background: The use of Imatinib mesylate in the first-line setting has changed the treatment landscape of GISTs. Im...
A retrospective cohort study evaluating cetuximab super-responders with recurrent or metastatic squamous cell carcinoma of the head and neck.
e18009 Background: Cetuximab is a key targeted therapy in squamous cell carcinoma of the head and neck (SCCHN), supported...